Hepatitis C virus genotype 3a: Predictive factors associated with treatment response in patients of Peshawar.

  • Amina Gul Khyber Medical College, Peshawar, Pakistan.
  • Naheed Gul Shifa College of Medicine, Islamabad, Pakistan.
  • Ijaz Ali COMSATS Institute of Information Technology, Islamabad, Pakistan.
  • Jawad Ahmed Institute of Basic Medical Sciences, Khyber Medical University, Peshawar, Pakistan.
Keywords: EVR, Genotype, HCV 3a, HCV infection, Ribavirin, Sofosbuvir

Abstract

Hepatitis C Virus (HCV) is a flavivirus responsible for causing chronic liver diseases including cirrhosis and hepatocellular carcinoma. Identification of various patient and virus-related factors that can help predict response to antiviral therapy is extremely important in formulating the best therapeutic strategy for each patient either to continue or stop the therapy. The present study aimed to determine Sustained Virological Response (SVR) in HCV genotype 3a infected patients that received combination therapy of Sofosbuvir and Ribavirin and to investigate various factors that can help predict SVR. Study Design: Longitudinal Study Settings: Institute of basic Medical Sciences, Khyber Medical University, Peshawar (IBMS, KMU). Period: July 2016 to September 2017. Materials and Methods: Treatment response was evaluated among 100 HCV genotype 3a infected patients that received Sofosbuvir and Ribavirin therapy for 24 weeks. Various baseline parameters including hematological, biochemical and viral profiles of were recorded. HCV genotype determination was carried out by type specific nested PCR based genotyping assay. Viral load was determined at baseline, at 12 weeks for Early Virological Response (EVR) and at 24 weeks of treatment for SVR. Viral RNA quantification was carried out by Real Time PCR. Results: Out of 100 patients, SVR was observed in 83% of patients; while 17% of the chronic HCV 3a infected patients were Non-Responders (NR). Mean age of patients was low 34 ± 9.8 among patients who achieved SVR as compared to patients with non-response (41 ± 10). The 24 weeks Alanine aminotransferase (ALT) levels were significantly lower among patients with SVR (p-value ≤ 0.05). Although statistically not significant, baseline viral load was higher in NR group (p-value ≥ 0.05), than those with SVR. Association of EVR with SVR was found statistically significant (OR= 2.8, 95% CI 1.2-6.4, p-value ≤ 0.05). Conclusions: The current study indicated that pre and on-treatment monitoring of patients receiving anti-viral therapy is important for the management of patients with chronic HCV infection. 

Author Biographies

Amina Gul, Khyber Medical College, Peshawar, Pakistan.

MBBS, DCP, PhD Microbiology

Assistant Professor

Department of Pathology

 

Naheed Gul, Shifa College of Medicine, Islamabad, Pakistan.

FCPS Internal Medicine

Associate Professor

Department of Medicine

 

Ijaz Ali, COMSATS Institute of Information Technology, Islamabad, Pakistan.

PhD

Associate Professor

Department of Biosciences

 

Jawad Ahmed, Institute of Basic Medical Sciences, Khyber Medical University, Peshawar, Pakistan.

PhD

Professor and Dean

 

Published
2019-08-10